Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.03% of ...

Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI ...

The stock's fall snapped a two-day winning streak.

This week, the FDA granted priority review status to J&J’s JNJ application seeking approval of key pipeline candidate ...

Pfizer Inc. (NYSE:PFE – Get Free Report)’s share price fell 0.8% during trading on Thursday after UBS Group lowered their price target on the stock from $31.00 to $29.00. UBS Group currently has a ...

This was the stock's second consecutive day of gains.

Pfizer (PFE) closed the most recent trading day at $26.91, moving -0.83% from the previous trading session. This change lagged the S&P 500's 0.16% gain on the day. Meanwhile, the Dow experienced a ...

PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...

The board of Pfizer Inc. ( NYSE:PFE ) has announced that it will be paying its dividend of $0.43 on the 7th of ...

The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...

Pfizer plans to achieve $4 billion in savings, invest in key areas like oncology and vaccines, and project double-digit EPS ...

At the same time, the expiration of key patents is coming up for some major Pfizer drugs, including blood thinner Eliquis and ...